0.83
+0.0345(+4.35%)
Currency In USD
| Previous Close | 0.79 |
| Open | 0.8 |
| Day High | 0.83 |
| Day Low | 0.8 |
| 52-Week High | 1.87 |
| 52-Week Low | 0.54 |
| Volume | 122,012 |
| Average Volume | 140,498 |
| Market Cap | 9.65M |
| PE | -0.55 |
| EPS | -1.5 |
| Moving Average 50 Days | 0.97 |
| Moving Average 200 Days | 0.86 |
| Change | 0.03 |
If you invested $1000 in Biofrontera Inc. (BFRI) since IPO date, it would be worth $9.39 as of December 04, 2025 at a share price of $0.828. Whereas If you bought $1000 worth of Biofrontera Inc. (BFRI) shares 3 years ago, it would be worth $39.43 as of December 04, 2025 at a share price of $0.828.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
GlobeNewswire Inc.
8 hours ago
Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2Completion of this study marks a key milestone towards a planned summer 2026 FDA submission for FDA app
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
GlobeNewswire Inc.
Dec 02, 2025 1:45 PM GMT
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to FDAPrimary and key secondary endpoints met with high
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
GlobeNewswire Inc.
Nov 07, 2025 1:00 PM GMT
Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash position, which is expected to fun